These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17453370)

  • 1. Oestrogen and progesterone receptor status of individual foci in multifocal invasive ductal breast cancer.
    Garimella V; Long ED; O'Kane SL; Drew PJ; Cawkwell L
    Acta Oncol; 2007; 46(2):204-7. PubMed ID: 17453370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for initial lung metastasis from breast invasive ductal carcinoma in stages I-III of operable patients.
    Gao D; Du J; Cong L; Liu Q
    Jpn J Clin Oncol; 2009 Feb; 39(2):97-104. PubMed ID: 19052036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
    Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oestrogen-progesterone receptor ratio: an indicator of breast cancer evolution.
    Cherubini M; Baxa P; Guarino G
    Chir Ital; 2002; 54(4):423-8. PubMed ID: 12239750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer.
    Biesterfeld S; Veuskens U; Schmitz FJ; Amo-Takyi B; Böcking A
    Anticancer Res; 1996; 16(5A):2497-500. PubMed ID: 8917341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oestrogen receptors revisited: long-term follow up of over five thousand breast cancer patients.
    Hähnel R; Spilsbury K
    ANZ J Surg; 2004 Nov; 74(11):957-60. PubMed ID: 15550082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
    Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
    Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer.
    Sharangpani GM; Joshi AS; Porter K; Deshpande AS; Keyhani S; Naik GA; Gholap AS; Barsky SH
    J Microsc; 2007 Jun; 226(Pt 3):244-55. PubMed ID: 17535263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive factors in breast cancer.
    Bundred NJ
    Cancer Treat Rev; 2001 Jun; 27(3):137-42. PubMed ID: 11417963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance.
    Yamauchi C; Hasebe T; Iwasaki M; Imoto S; Wada N; Fukayama M; Ochiai A
    Hum Pathol; 2007 Feb; 38(2):247-59. PubMed ID: 17056095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between telomerase activity and hormone receptor status and p53 expression in breast cancer.
    Mokbel K; Ghilchik M; Williams G; Akbar N; Parris C; Newbold R
    Int J Surg Investig; 2000; 1(6):509-16. PubMed ID: 11729859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
    van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
    Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
    Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
    Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients.
    Richter-Ehrenstein C; Müller S; Noske A; Schneider A
    Int J Surg Pathol; 2009 Aug; 17(4):323-6. PubMed ID: 19029173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclo-oxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer.
    McCarthy K; Bustin SA; Ogunkolade B; Khalaf S; Laban CA; McVittie CJ; Carpenter R; Jenkins PJ
    Eur J Surg Oncol; 2006 Sep; 32(7):707-9. PubMed ID: 16650963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of computer-assisted image analysis for the detection of immunohistochemical receptor status in breast cancer. Immunohistochemical densitometry receptor analysis--IRDA].
    Mink D; Bonkhoff H; Herth G; Schmidt W
    Geburtshilfe Frauenheilkd; 1992 Oct; 52(10):617-23. PubMed ID: 1294438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer.
    Park SY; Kim KS; Lee TG; Park SS; Kim SM; Han W; Noh DY; Kim SW
    Am J Surg; 2009 Feb; 197(2):266-9. PubMed ID: 18614146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC 11.
    Angus B; Napier J; Purvis J; Ellis IO; Hawkins RA; Carpenter F; Horne CH
    J Pathol; 1986 Aug; 149(4):301-6. PubMed ID: 3020217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
    Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.